Seeking Alpha

Flamel Technologies S.A. (FLML)

  • Nov. 28, 2014, 9:49 AM
    • Lyon, France-based Flamel Technologies (FLML +0.6%) sells its Pessac, France-located manufacturing and development facility to Swedish CDMO (contract development and manufacturing organization) Recipharm for €10.6M as part of a five-year service agreement. Flamel retains access to the capabilities of Pessac as well as other Recipharm facilities for its production and development activities. The sale includes the royalty contract for Coreg CR with GlaxoSmithKline (GSK +0.3%).
    • Flamel and Recipharm agree to negotiate an agreement with the objective of incorporating the former's drug delivery technology into the latter's contract development business.
    • In a separate transaction, Recipharm will make a €10.5M investment in Flamel's common stock.
    | Nov. 28, 2014, 9:49 AM | Comment!
  • Mar. 15, 2012, 9:29 AM
    Flamel Technologies (FLML) -19% premarket after agreeing to acquire specialty drug maker Eclat Pharmaceuticals in a debt-and-warrant deal and named Eclat's chief executive to replace its own CEO.
    | Mar. 15, 2012, 9:29 AM | Comment!
Company Description
Flamel Technologies is a specialty pharmaceutical company. The Company is engaged in drug delivery and formulation to develop safer and more efficacious pharmaceutical products to address unmet medical needs and reduce overall healthcare costs.
Sector: Healthcare
Country: France